DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: BETASERON (interferon beta-1b, Betaferon, Extavia)
       *****************************************************
       #Post#: 931--------------------------------------------------
       (Abst.) 10-yr. follow up of European multicenter trial of Betase
       ron in SPMS
       By: agate Date: September 13, 2015, 7:29 pm
       ---------------------------------------------------------
       From PubMed, September 13, 2015:
       [quote]Mult Scler. 2015 Sep 11. pii: 1352458515594440.
       A 10-year follow-up of the European multicenter trial of
       interferon β-1b in secondary-progressive multiple sclerosis
       Kuhle J1, Hardmeier M2, Disanto G3, Gugleta K2, Ecsedi M2,
       Lienert C4, Amato MP5, Baum K6, Buttmann M7, Bayas A8, Brassat
       D9, Brochet B10, Confavreux C11, Edan G12, Färkkilä M13,
       Fredrikson S14, Frontoni M15, D'Hooghe M16, Hutchinson M17, De
       Keyser J18, Kieseier BC19, Kümpfel T20, Rio J21, Polman C22,
       Roullet E23, Stolz C24, Vass K25, Wandinger KP26, Kappos L27;
       European Long-term Follow-up Study Group in Interferon β-1b
       in Secondary-progressive Multiple Sclerosis.
       Author information:  [The authors are from the UK, Germany,
       France, Italy, Switzerland, Spain, Austria, and the Netherlands]
       OBJECTIVES:
       To explore long-term effects of treatment and prognostic
       relevance of variables assessed at baseline and during the
       European secondary progressive multiple sclerosis (SPMS) trial
       of interferon beta 1b (IFNB-1b).
       METHODS:
       We assessed 362 patients (60% female; median age 41 years;
       Expanded Disability Status Scale (EDSS): 5.5; 51% randomized to
       IFNB-1b) for their EDSS and treatment history after 10 years.
       Non-parametric analysis of covariance (ANCOVA) and multivariate
       linear regression models were applied.
       RESULTS:
       Median EDSS was 6.0 at the end of the randomized controlled
       trial (RCT), in the IFNB-1b and placebo groups, and 7.0 in
       long-term follow-up patients (those receiving IFNB-1b in the RCT
       were 6.5 and those receiving placebo in the RCT were 7.0; p =
       0.086). 24 patients (6.6%) were deceased. The EDSS at baseline
       and the EDSS change during the RCT were the most important
       predictors of the EDSS 10 years later (partial R2: 0.47). The
       ability to predict changes in EDSS 10 years after the RCT was
       limited (R2: 0.12). Magnetic resonance imaging (MRI) measures
       remained in the predictive models, but explained < 5% of the
       variability.
       CONCLUSIONS:
       The results from this analysis did not provide convincing
       evidence to support a favorable long-term outcome in those
       patients allocated IFNB-1b during the RCT, in our SPMS cohort.
       The progressive stage of the disease remains largely
       unpredictable by clinical and conventional MRI measures, so
       better prognostic markers are needed.[/quote]
       The abstract can be seen here
  HTML http://www.ncbi.nlm.nih.gov/pubmed/26362898.
       *****************************************************